Scarica l'app Stockscreener
15.09
4.25%
-0.67
Dopo l'orario di chiusura:
14.90
-0.19
-1.26%
Precedente Chiudi:
$15.76
Aprire:
$15.76
Volume 24 ore:
76,473
Relative Volume:
0.41
Capitalizzazione di mercato:
$971.76M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-15.00
EPS:
-1.0062
Flusso di cassa netto:
-
1 W Prestazione:
-2.83%
1M Prestazione:
+8.91%
6M Prestazione:
+84.47%
1 anno Prestazione:
+750.14%
Intervallo 1D:
$14.82
$15.80
Intervallo di 1 settimana:
$14.82
$16.31
Portata 52W:
$0.8786
$17.25
Adlai Nortye Ltd Adr Stock (ANL) Company Profile
Nome
Adlai Nortye Ltd Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare ANL vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANL
Adlai Nortye Ltd Adr
|
15.09 | 1.00B | 0 | 0 | 0 | -1.0062 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adlai Nortye Ltd Adr Stock (ANL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-20 | Iniziato | Leerink Partners | Outperform |
| 2026-02-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-06-02 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-09-04 | Iniziato | H.C. Wainwright | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
Adlai Nortye Ltd Adr Borsa (ANL) Ultime notizie
Adlai Nortye Names Christopher Liu as Head of Investor and Public Relations - TipRanks
Adlai Nortye Group Ltd. (ANL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Adlai Nortye Shareholders Approve All Resolutions at September 30 Extraordinary Meeting - TipRanks
Adlai Nortye director Ji Ping sells $83,150 in shares By Investing.com - Investing.com South Africa
Adlai Nortye director Ji Ping sells $83,150 in shares - Investing.com
Form 4 Adlai Nortye Ltd ADR For: 26 September By Investing.com - Investing.com Nigeria
Adlai Nortye at Morgan Stanley global healthcare conference: RAS push By Investing.com - Investing.com South Africa
Adlai Nortye (NASDAQ: ANL) readies new offerings as holders plan a large ADS resale - Stock Titan
Jefferies initiates Adlai Nortye stock with buy rating on drug potential - Investing.com Australia
Adlai Nortye (NASDAQ: ANL) Initiates Global Phase I Trial for AN4035 with Phase Ia Data Expected in Late 2027 - Kalkine Media
Adlai Nortye Launches Global Phase I Trial of First-in-Class RAS-Targeting ADC AN4035 - TipRanks
Lucid Capital Markets initiates Adlai Nortye stock with buy rating By Investing.com - Investing.com Nigeria
Lucid Capital Markets initiates Adlai Nortye stock with buy rating - investing.com
Adlai Nortye doses first patient in AN4035 cancer trial By Investing.com - Investing.com Canada
Adlai Nortye doses first patient in AN4035 cancer trial - Investing.com
Analysts Offer Insights on Healthcare Companies: Sysmex (OtherSSMXF) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye CFO Ye Xiaofeng Reports Sale of 11,667 ADS in Two Open-Market Transactions - Kalkine Media
Adlai Nortye Calls September Extraordinary Meeting to Authorize Major Share Issuance and Board Changes - TipRanks
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
Adlai Nortye Redomiciles to Singapore and Updates Nasdaq Identity - TipRanks
Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares - Stock Titan
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High? - Yahoo Finance
HC Wainwright Increases Earnings Estimates for Adlai Nortye - MarketBeat
Adlai Nortye (NASDAQ:ANL) Stock Price Up 6.2%Still a Buy? - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Adlai Nortye Boosts Cash Reserves and Advances RAS-Focused Oncology Pipeline in First Half of 2026 - TipRanks
Adlai Nortye (ANL) Earnings Date and Reports 2026 $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adlai Nortye (ANL) Sheds 0.75% to $13.18 as Biotech ADR Holds Above Key SupportMoney Flow Index - dars.gov.et
Adlai Nortye Initiated at Buy as First-in-Class RASiCA ADC Enters Clinic; $20 Price Target Reiterated - TipRanks
Adlai Nortye receives approval to begin trial in Australia - Investing.com
Adlai Nortye Wins Australian Clearance to Launch First-in-Class Pan-RAS(ON) ADC Trial - TipRanks
ADAR1 Capital Management LLC Makes New $816,000 Investment in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Affinity Asset Advisors LLC Takes Position in Adlai Nortye Ltd. Sponsored ADR $ANL - MarketBeat
Adlai Nortye Ltd. Sponsored ADR (ANL) Receives a Buy from Cantor Fitzgerald - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Adlai Nortye Begins Weekly Dosing Arm in Global Phase 1 Trial of RAS Inhibitor AN9025 - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV) - The Globe and Mail
Adlai Nortye: Buy Rating Reaffirmed as Dual-Arm AN9025 Strategy Advances; $20 Price Target Maintained - TipRanks
Adlai Nortye doses first patient in weekly trial arm of AN9025 - Investing.com
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com - Investing.com Nigeria
Adlai Nortye expands scientific advisory board with two oncologists - Investing.com
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0 - TradingView
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL) - TradingView
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0 - TradingView
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating By Investing.com - Investing.com Nigeria
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Adlai Nortye Ltd Adr Azioni (ANL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):